This experiment describes more commonly encountered scenarios in drug discovery projects, where multiple objectives might be optimized simultaneously. We consider the task of generating molecules that are not only potential DRD2 binders but also tailored for high drug-likeness and minimal hERG bioactivity (i.e., minimizing the risk of hERG channel activation and subsequent arrhythmia ).